NCT04387617View on ClinicalTrials.gov

A Study to Assess the Effect of Cannabidiol Oil on Pain After Ureteroscopy for Kidney Stones

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

February 15, 2021

Primary Completion Date

January 31, 2022

Study Completion Date

January 31, 2022

Conditions
Urinary Stone
Interventions
DRUG

Cannabidiol

The product is a liquid formulation that will be prescribed at a dosage of 20 mg per day for a total of 3 days.

DRUG

Placebo

The product is a liquid formulation placebo that will be prescribed at an equivalent volume as active drug for 3 days

Trial Locations (1)

85054

Mayo Clinic in Arizona, Phoenix

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT04387617 - A Study to Assess the Effect of Cannabidiol Oil on Pain After Ureteroscopy for Kidney Stones | Biotech Hunter | Biotech Hunter